Early Circulation of SARS-CoV-2, Congo, 2020
Novy Charel Bobouaka Bonguili
1, Matthieu Fritz
1, Leadisaelle Hosanna Lenguiya, Pembe Issamou Mayengue, Félix Koukouikila-Koussounda, Louis Régis Dossou-Yovo, Cynthia Nkoua Badzi, Eric M. Leroy, and Fabien R. Niama
Author affiliations: Laboratoire National de Santé Publique, Brazzaville, Republic of Congo (N.C. Bobouaka Bonguili, L.H. Lenguiya, P. Issamou Mayengue, F. Koukouikila-Koussounda, L.R. Dossou-Yovo, C. Nkoua Badzi, F.R. Niama); Université Marien Ngouabi, Brazzaville (N.C. Bobouaka Bonguili, L.H. Lenguiya, P. Issamou Mayengue, F. Koukouikila-Koussounda, L.R. Dossou-Yovo, F.R. Niama); Université de Montpellier, Montpellier, France (M. Fritz, E.M. Leroy); Institut de Recherche pour le Développement, Unité Mixte de Recherche MIVEGEC, Montpellier (M. Fritz, E.M. Leroy)
Main Article
Figure
Figure. Number of plasma samples tested each month for severe acute respiratory syndrome coronavirus antibodies by using a microsphere immunoassay with beads coupled with receptor-binding domain antigen, Congo, September 2019–February 2020. Gray shading indicates the number of seronegative samples; orange, seropositive samples. Seropositivity is represented by black dots; error bars indicate 95% binomial CIs.
Main Article
Page created: February 07, 2022
Page updated: March 19, 2022
Page reviewed: March 19, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.